Neuro-Oncology

Papers
(The H4-Index of Neuro-Oncology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary5698
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018944
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019641
EANO guideline on the diagnosis and management of meningiomas311
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter225
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial205
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020168
Epidemiology of brain metastases and leptomeningeal disease167
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018134
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications127
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis122
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial121
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma117
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group97
A molecularly integrated grade for meningioma94
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance92
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification91
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study91
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)89
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR88
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group85
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors80
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults80
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors78
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors74
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery74
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions73
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification70
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)69
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma69
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank68
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity67
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors64
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study63
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma63
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions63
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma62
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)58
A serum-based DNA methylation assay provides accurate detection of glioma57
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial55
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications55
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas54
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions53
TGF-β promotes microtube formation in glioblastoma through thrombospondin 153
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial52
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)52
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma52
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas51
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study51
Loss of H3K27me3 in meningiomas50
0.065609931945801